Bavarian Nordic's Largest Shareholder Stands Firm Against $3.1 Billion Private-Equity Takeover Bid

Core Viewpoint - ATP has rejected a sweetened bid from private-equity firms for the vaccine maker, raising concerns about the likelihood of the deal being completed [1] Group 1 - The rejection of the bid indicates potential challenges in the acquisition process for the vaccine maker [1] - The involvement of private-equity firms suggests significant interest in the vaccine sector, which may impact future investment dynamics [1]